STOCK TITAN

iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

iBio (IBIO) reported extended preclinical findings for its IBIO-610 antibody candidate and animal data from its amylin program.

In obese non-human primates, IBIO-610 produced a 2.3% vehicle-adjusted reduction in body weight from baseline at week 28. At week 24, total body fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower and visceral fat 10.96% lower than vehicle; lean mass was generally maintained. Near-complete suppression of active Activin E persisted through week 28. The study included five treated animals and six vehicle controls; dosing was initially every eight weeks, followed by more frequent dosing and a dose-free period.

The amylin antibody-peptide fusion selectively activated amylin receptors 1 and 3 in laboratory testing and reduced food intake over 24 hours in a single-dose lean-rat study versus vehicle. iBio plans further preclinical studies in diet-induced obesity models.

Loading...
Loading translation...

Positive

  • Minor pointIBIO-610 achieved a 2.3% vehicle-adjusted reduction in body weight from baseline at week 28 in obese non-human primates.
  • Minor pointIBIO-610 total body fat was 9.6% lower than vehicle at week 24.
  • Minor pointIBIO-610 abdominal subcutaneous fat was 16.6% lower than vehicle at week 24.
  • Minor pointIBIO-610 visceral fat was 10.96% lower than vehicle at week 24.
  • Minor pointIBIO-610 generally maintained lean mass in the obese non-human primate study.
4 minor points
  • Minor pointIBIO-610 maintained near-complete suppression of active Activin E through week 28.
  • Minor pointAmylin fusion selectively bound and activated receptors 1 and 3, with minimal calcitonin-receptor binding or activation alone.
  • Minor pointAmylin agonist reduced food intake over 24 hours versus vehicle in a single-dose lean-rat study.
  • Minor point. Forward-looking: it has not happened yet and may not happen.iBio plans further preclinical testing of selective amylin receptor agonists in diet-induced obesity models.

Negative

  • None.

Key Figures

Body-weight difference: 2.3% Total body fat: 9.6% lower Abdominal subcutaneous fat: 16.6% lower +2 more
Body-weight difference
2.3%
Vehicle-adjusted reduction from baseline at week 28
Total body fat
9.6% lower
Compared with vehicle at week 24
Abdominal subcutaneous fat
16.6% lower
Compared with vehicle at week 24
Visceral fat
10.96% lower
Compared with vehicle at week 24
NHP study groups
IBIO-610: n=5; vehicle: n=6
Obese non-human primate study

Historical Context

1 past event · Latest: Oct 13
1 event
  1. Oct 13

    NHP study data

    24h Move
    -13.4%

    Earlier NHP data: lean mass was 6% of combination weight loss versus 22% with semaglutide.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-human primate (nhp), amylin receptor agonist, calcitonin receptor, in vitro
4 terms
non-human primate (nhp) medical
"extending observations through 28 weeks in a non-human primate (NHP) study."
Non-human primate (NHP) refers to monkeys, apes or other primate species used in medical research to test safety and effectiveness before treatments are given to people. Because their biology is closer to humans than other lab animals, results from NHP studies can strongly influence whether regulators allow human trials, how quickly a drug advances, and the cost, timing and risk profile investors use to value biotech projects — like a dress rehearsal that helps predict real-world performance.
amylin receptor agonist medical
"iBio’s selective amylin receptor agonist had reduced food intake"
An amylin receptor agonist is a drug that activates the body’s amylin receptors to mimic the hormone amylin, which helps slow stomach emptying, reduce appetite, and regulate blood sugar. For investors, these medicines matter because clinical trial results, safety profiles, and regulatory approval determine their commercial potential in diabetes and obesity markets—similar to how a new feature can change a product’s appeal and sales prospects.
calcitonin receptor medical
"minimal binding to or activation of the calcitonin receptor alone."
A cell-surface receptor protein that binds the hormone calcitonin and, when activated, triggers intracellular signaling pathways that influence calcium handling and bone resorption. The calcitonin receptor is a G‑protein–coupled receptor whose functional properties and which peptides it responds to can change when it pairs with receptor activity–modifying proteins (RAMPs); those pairings alter ligand specificity and tissue distribution, so effects depend on the receptor’s molecular partners and where it is expressed in the body.
in vitro technical
"In vitro, iBio’s antibody-peptide fusion selectively bound and activated"
In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.

Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit

Together, the findings highlight the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced extended preclinical data from a non-human primate (NHP) study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical data from its amylin program to be presented at PEGS Europe 2026 and the Amylin-Based Therapeutics Summit.

“These data demonstrate the power of our AI-enabled antibody discovery platform to generate potent, highly specific molecules against challenging targets,” said Martin Brenner, DVM, Ph.D., chief executive officer and chief scientific officer of iBio. “The sustained effects observed in our NHP study strengthen our belief in IBIO-610’s potential to offer a differentiated approach to long-term weight management. Durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight provide a more comprehensive perspective of how this approach may improve the quality of weight loss. Beyond IBIO-610, our amylin program has taken an important step forward, demonstrating high selectivity for amylin receptors and reduced food intake in a preclinical model. We believe this selective approach has the potential to improve the balance of efficacy and tolerability and look forward to evaluating it in further studies. By pursuing multiple distinct mechanisms, we have the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies.”

IBIO-610 Activin E Data presented at ObesityWeek 2026
The new data for iBio’s long-acting Activin E-targeting antibody, IBIO-610, builds on previously reported findings from an obese NHP study, extending observations through 28 weeks.

The study included obese NHPs receiving IBIO-610 (n=5) or vehicle (n=6). IBIO-610 was initially administered every eight weeks, followed by more frequent dosing and a dose-free period.

Key findings:

  • IBIO-610 reduced weight gain despite continued high-fat feeding, with body weight beginning to diverge from the vehicle group around Week 18 and reaching a 2.3% difference by Week 28.

  • At Week 24, total body fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower, and visceral fat 10.96% lower compared with vehicle, while lean mass was generally maintained.

  • Near-complete suppression of active Activin E was observed through week 28.

These findings build on previously reported data from the NHP study and further support IBIO-610’s potential to promote fat-selective effects while maintaining lean mass.

Amylin Program Data to Be Presented at PEGS Europe and the Amylin-Based Therapeutics Summit

iBio’s amylin program combines a receptor-targeting antibody with a fused peptide agonist and demonstrated highly selective activation of amylin receptors 1 and 3. The findings highlight the platform’s ability to generate highly specific antibodies against challenging targets and support the development of a potential long-acting amylin therapeutic.

Key findings:

  • In vitro, iBio’s antibody-peptide fusion selectively bound and activated amylin receptors 1 and 3, with minimal binding to or activation of the calcitonin receptor alone.

  • In a single-dose study in lean rats, the rats dosed with iBio’s selective amylin receptor agonist had reduced food intake over 24 hours compared with vehicle.

iBio plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models.

Presentation Details:

ObesityWeek 2026
Title: Deep, Durable Activin E Suppression by Antibody Blockade Drives Fat-Selective Effects in Obese Non-Human Primates
Format: Poster
Date and time: Sunday, November 15, 2026, 2:30–3:30 p.m. ET
Presenter: Cory Schwartz
Location: Gaylord National Resort & Convention Center, National Harbor, Maryland

PEGS Europe 2026
Title: Beyond Peptides: Engineering GPCR Agonists for Next-Generation Cardiometabolic Therapeutics
Format: Oral presentation
Date and time: Thursday, November 19, 2026, at 11:15 a.m. WET
Presenter: Cody Moore
Location: Lisbon Congress Center, Lisbon, Portugal

Amylin-Based Therapeutics Summit
Title: Decoding Amylin Receptor Specificity to Engineer a More Precise, Long-Acting Therapeutic
Format: Presentation
Presenter: Cody Moore
Date and time: Wednesday, December 2, 2026, at 1:30 p.m. ET
Location: Wyndham Boston Beacon Hill

Title: Navigating the Efficacy–Tolerability Trade-off: Linking Half-Life, Dosing and Clinical Outcomes to Define Amylin’s Competitive Advantage
Format: Workshop
Leader: Cory Schwartz
Date and time: Tuesday, December 1, 2026, at 1:00 p.m. ET
Location: Wyndham Boston Beacon Hill

About iBio, Inc.
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

For more information, visit www.ibioinc.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among others, statements regarding the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets; IBIO-610 potentially being a first-in-class Activin E antibody candidate; IBIO-610’s potential to offer a differentiated approach to long-term weight management; durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight providing a more comprehensive perspective of how the approach may improve the quality of weight loss; the amylin program’s approach having the potential to improve the balance of efficacy and tolerability; iBio evaluating the selective approach in further studies; having the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies; the findings further supporting IBIO-610’s potential to promote fat-selective effects while maintaining lean mass; the development of a potential long-acting amylin therapeutic iBio plans to advance selective amylin receptor agonists into further preclinical studies in diet-induced obesity models. These statements reflect iBio’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with the possibility that preclinical findings will not be replicated in humans, iBIO’s ability to successfully develop products, including products for long-term weight management; durable Activin E suppression, reductions in fat mass while generally maintaining lean mass and iBio’s ability to obtain regulatory approval or any of its products, and the other risks described in iBio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026, and subsequent filings.

Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.

Investor Contact
Matt Beck
astr partners
matthew.beck@astrpartners.com
(917) 415-1750

Media Contact
Jason Braco, Ph.D.
Valence Communications
jason@valencecomms.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did iBio’s IBIO-610 preclinical study show at week 28?

IBIO-610 showed a 2.3% vehicle-adjusted reduction in body weight from baseline at week 28 in obese non-human primates. Near-complete suppression of active Activin E was also observed through week 28. The study included five animals receiving IBIO-610 and six receiving vehicle.

What did iBio’s amylin program show in preclinical testing?

iBio’s amylin antibody-peptide fusion selectively activated amylin receptors 1 and 3 in laboratory testing, and its selective agonist reduced food intake over 24 hours versus vehicle in a single-dose lean-rat study. iBio plans further preclinical studies in diet-induced obesity models.

Keep reading